SynBioBeta Speaker

Avantika Lal

Genentech

Principal ML Scientist II

I am a researcher working at the cross-section of machine learning and genomics. The goal of my research is to use deep learning models to understand the regulatory syntax of the human genome, reveal the molecular mechanisms underlying complex diseases, and design new therapeutics.

Sessions Featuring

Avantika

This Year

Breakout Session

•

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Featuring

Andrei Georgescu

Vivodyne

CEO

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Avantika Lal

Genentech

Principal ML Scientist II

Building DNA foundation models that design regulatory sequences.

Daniel Georgiev

Sampling Human

CEO & Co-founder

Krish Ramadurai

AIX Ventures

Partner

TechBio investor backing AI-designed drugs and breakthroughs.

Breakout Session

•

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Featuring

Andrei Georgescu

Vivodyne

CEO

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Avantika Lal

Genentech

Principal ML Scientist II

Building DNA foundation models that design regulatory sequences.

Daniel Georgiev

Sampling Human

CEO & Co-founder

Krish Ramadurai

AIX Ventures

Partner

TechBio investor backing AI-designed drugs and breakthroughs.

Previous Speakers Include